JP2021138693A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021138693A5 JP2021138693A5 JP2021031341A JP2021031341A JP2021138693A5 JP 2021138693 A5 JP2021138693 A5 JP 2021138693A5 JP 2021031341 A JP2021031341 A JP 2021031341A JP 2021031341 A JP2021031341 A JP 2021031341A JP 2021138693 A5 JP2021138693 A5 JP 2021138693A5
- Authority
- JP
- Japan
- Prior art keywords
- administered
- acceptable salt
- compound
- pharmaceutically acceptable
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022183924A JP2023009250A (ja) | 2020-03-03 | 2022-11-17 | がんを処置するための方法 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062984458P | 2020-03-03 | 2020-03-03 | |
| US62/984458 | 2020-03-03 | ||
| US202163133501P | 2021-01-04 | 2021-01-04 | |
| US63/133501 | 2021-01-04 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022183924A Division JP2023009250A (ja) | 2020-03-03 | 2022-11-17 | がんを処置するための方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021138693A JP2021138693A (ja) | 2021-09-16 |
| JP2021138693A5 true JP2021138693A5 (enExample) | 2022-03-09 |
| JP7181325B2 JP7181325B2 (ja) | 2022-11-30 |
Family
ID=74860342
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021031341A Expired - Fee Related JP7181325B2 (ja) | 2020-03-03 | 2021-03-01 | がんを処置するための方法 |
| JP2022183924A Pending JP2023009250A (ja) | 2020-03-03 | 2022-11-17 | がんを処置するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022183924A Pending JP2023009250A (ja) | 2020-03-03 | 2022-11-17 | がんを処置するための方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230117328A1 (enExample) |
| EP (1) | EP4114397A1 (enExample) |
| JP (2) | JP7181325B2 (enExample) |
| KR (1) | KR20220148867A (enExample) |
| CN (1) | CN115529816A (enExample) |
| AU (1) | AU2021231435A1 (enExample) |
| BR (1) | BR112022017267A2 (enExample) |
| CA (1) | CA3174064A1 (enExample) |
| IL (1) | IL296060A (enExample) |
| MX (1) | MX2022010955A (enExample) |
| TW (2) | TWI775333B (enExample) |
| WO (1) | WO2021176330A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023002360A1 (en) * | 2021-07-22 | 2023-01-26 | Pfizer Inc. | Solid forms and formulations of an inhibitor of tam and c-met kinases |
| CN122140719B (zh) * | 2026-04-15 | 2026-07-28 | 广州市第一人民医院（广州消化疾病中心、广州医科大学附属市一人民医院、华南理工大学附属第二医院） | Sgi-7079在治疗flt3突变型急性髓系白血病中的应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| PT2242773T (pt) | 2008-02-11 | 2017-09-15 | Cure Tech Ltd | Anticorpos monoclonais para o tratamento de tumores |
| WO2010098788A2 (en) | 2008-08-25 | 2010-09-02 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| US10195208B2 (en) * | 2014-07-31 | 2019-02-05 | Novartis Ag | Combination therapy |
| WO2016019270A1 (en) | 2014-07-31 | 2016-02-04 | Academia Sinica | An antagonistic pd-1 aptamer and its applications in cancer therapy related applications |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| UY38349A (es) * | 2018-08-30 | 2020-03-31 | Array Biopharma Inc | Compuestos de pirazolo[3,4-b]piridina como inhibidores de cinasas tam y met |
-
2021
- 2021-03-01 BR BR112022017267A patent/BR112022017267A2/pt not_active Application Discontinuation
- 2021-03-01 AU AU2021231435A patent/AU2021231435A1/en not_active Abandoned
- 2021-03-01 EP EP21710583.2A patent/EP4114397A1/en not_active Withdrawn
- 2021-03-01 US US17/905,536 patent/US20230117328A1/en not_active Abandoned
- 2021-03-01 MX MX2022010955A patent/MX2022010955A/es unknown
- 2021-03-01 WO PCT/IB2021/051693 patent/WO2021176330A1/en not_active Ceased
- 2021-03-01 JP JP2021031341A patent/JP7181325B2/ja not_active Expired - Fee Related
- 2021-03-01 IL IL296060A patent/IL296060A/en unknown
- 2021-03-01 CN CN202180027637.8A patent/CN115529816A/zh active Pending
- 2021-03-01 CA CA3174064A patent/CA3174064A1/en active Pending
- 2021-03-01 KR KR1020227033740A patent/KR20220148867A/ko not_active Withdrawn
- 2021-03-02 TW TW110107282A patent/TWI775333B/zh not_active IP Right Cessation
- 2021-03-02 TW TW111128154A patent/TWI814504B/zh not_active IP Right Cessation
-
2022
- 2022-11-17 JP JP2022183924A patent/JP2023009250A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101950044B1 (ko) | Ａｋｔ 억제제 화합물 및 베무라페닙의 조합물, 및 사용 방법 | |
| EP3173100B1 (en) | Therapeutic combination comprising a cdks inhibitor and oxaliplatin | |
| AU2009279771B2 (en) | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine | |
| TWI685341B (zh) | 阿帕替尼和c-Met抑制劑聯合在製備治療腫瘤的藥物中的用途 | |
| JP2009514870A5 (enExample) | ||
| JP2020536971A5 (enExample) | ||
| AU2017277478B2 (en) | Pharmaceutical combinations for treating cancer | |
| WO2006120557A1 (en) | Anticancer combination therapy using sunitinib malate | |
| JP2019525948A5 (enExample) | ||
| JP2016147912A (ja) | 乳癌のための、ネラチニブを活用する治療計画 | |
| JP7179174B2 (ja) | スルホンアミド化合物と免疫調節剤を用いるがん併用療法 | |
| JP2019501185A (ja) | 食道癌を治療するためのキノリン誘導体の使用とその治療方法、医薬組成物及びキット | |
| JP2021515016A5 (enExample) | ||
| RU2020126340A (ru) | Способы и комбинированное терапевтическое средство для лечения рака | |
| US20110129467A1 (en) | Therapeutic combination comprising an aurora kinase inhibitor and antiproliferative agents | |
| TWI848990B (zh) | 治療化療難治性癌症的新聯合用藥方案 | |
| CN101163473A (zh) | 使用舒尼替尼苹果酸盐的抗癌组合疗法 | |
| EP2344156B1 (en) | Therapeutic combination comprising an aurora kinase inhibitor and an antineoplastic agent | |
| CN110402151A (zh) | 三氟尿苷/盐酸替吡嘧啶、抗肿瘤铂配合物和免疫关卡调节剂之间的组合 | |
| HK40113079A (en) | Antineoplastic combinations of neratinib and capecitabine | |
| JP2025512992A (ja) | Ｇｃｎ２モジュレーター化合物 | |
| HK40091861A (en) | Antineoplastic combinations of 4-anilino-3-cyanoquinolines and capecitabine | |
| JP2024506314A (ja) | がん治療のための併用療法 | |
| TW202015680A (zh) | 抗腫瘤劑及腫瘤治療方法 | |
| HK1239521B (en) | Antineoplastic combinations of neratinib and capecitabine |